Literature DB >> 30887201

A preliminary study to propose a diagnostic algorithm for PET/CT-detected incidental breast lesions: application of BI-RADS lexicon for US in combination with SUVmax.

Mehrdad Bakhshayeshkaram1, Yalda Salehi2, Mehrshad Abbasi2, Razieh Hashemi Beni1, Sharareh Seifi3, Maryam Hassanzad4, Hamid Reza Jamaati5, Farahnaz Aghahosseini6.   

Abstract

OBJECTIVES: To develop a diagnostic algorithm for positron emission tomography (PET)-detected incidental breast lesions using both breast imaging reporting and data system (BI-RADS) and maximum standardized uptake value (SUVmax) criteria.
METHODS: Fifty-six PET-detected incidental breast lesions from 51 patients, which were subsequently investigated by breast ultrasound within 1 month of the PET study, constituted the study cohort and they were finally verified by tissue diagnosis or a 2-year follow-up. Based on the maximum specificity with sensitivity > 60.0% and maximum sensitivity with specificity > 60.0%, two SUVmax cutoff values were calculated at 2 and 3.7. BI-RADS ≥ 4 was considered as highly suspicious for malignancy. The diagnostic accuracies were estimated for SUVmax levels above or below the cutoff points combined with the BI-RADS suspicion level.
RESULTS: Overall, 46 benign and 10 malignant lesions were studied. The diagnostic characteristics of SUVmax ≥ 2, SUVmax ≥ 3.7, and BI-RADS ≥ 4 were 80.0%, 60.0%, and 80.0% for sensitivity, 73.9%, 95.7%, and 92.7% for specificity, and 75.0%, 89.3%, and 90.2% for accuracy, respectively. When the SUVmax threshold was set at 2, combined with BI-RADS suspicion level, the sensitivity, specificity, and accuracy were 100.0%, 69.6%, and 75.0%, respectively. The results for SUVmax threshold set at 3.7 combined with BI-RADS were 90.0%, 91.3%, and 91.1% for the sensitivity, specificity, and accuracy, respectively. A diagnostic algorithm was accordingly generated.
CONCLUSION: The need for biopsy should be justified in low BI-RADS lesions presenting with high SUVmax at 3.7 or higher. The biopsy of patients with high B-IRADS and low SUVmax could be preserved. KEY POINTS: • A diagnostic algorithm was developed for PET-detected incidental breast lesions using both BI-RADS and SUVmax criteria. • Diagnostic performance was calculated separately and conjunctively for SUVmax ≥ 2, SUVmax ≥ 3.7, and BI-RADS ≥ 4. • The need for biopsy can be justified in BI-RADS < 4 lesions with SUVmax ≥ 3.7. Lesions with BI-RADS < 4 and indeterminate SUVmax (2 < SUVmax < 3.7) benefit from a short-interval follow-up. BI-RADS < 4 lesions with SUVmax < 2 may confidently be scheduled for routine screening.

Entities:  

Keywords:  18F-FDG; Breast; Diagnostic imaging; PET-CT

Mesh:

Year:  2019        PMID: 30887201     DOI: 10.1007/s00330-019-06106-x

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  35 in total

1.  BI-RADS for sonography: positive and negative predictive values of sonographic features.

Authors:  Andrea S Hong; Eric L Rosen; Mary S Soo; Jay A Baker
Journal:  AJR Am J Roentgenol       Date:  2005-04       Impact factor: 3.959

Review 2.  Benign breast lesions detected by positron emission tomography-computed tomography.

Authors:  Ana P Benveniste; Wei Yang; Marcelo F Benveniste; Osama R Mawlawi; Edith M Marom
Journal:  Eur J Radiol       Date:  2014-02-24       Impact factor: 3.528

3.  Imaging features of invasive lobular carcinoma: comparison with invasive ductal carcinoma.

Authors:  Sung Hun Kim; Eun Suk Cha; Chang Suk Park; Bong Joo Kang; In Yong Whang; A Won Lee; Byung Joo Song; Jeongmi Park
Journal:  Jpn J Radiol       Date:  2011-09-01       Impact factor: 2.374

4.  The accuracy of BI-RADS classification of breast ultrasound as a first-line imaging method.

Authors:  H Hille; M Vetter; B J Hackelöer
Journal:  Ultraschall Med       Date:  2011-08-29       Impact factor: 6.548

5.  Standardized uptake values for breast carcinomas assessed by fluorodeoxyglucose-positron emission tomography correlate with prognostic factors.

Authors:  Naoki Ikenaga; Naoki Otomo; Atsushi Toyofuku; Yuji Ueda; Kiyokazu Toyoda; Tohru Hayashi; Kiyoshi Nishikawa; Masao Tanaka
Journal:  Am Surg       Date:  2007-11       Impact factor: 0.688

Review 6.  Clinical applications of PET in brain tumors.

Authors:  Wei Chen
Journal:  J Nucl Med       Date:  2007-08-17       Impact factor: 10.057

7.  Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer.

Authors:  Rakesh Kumar; Anil Chauhan; Hongming Zhuang; Prem Chandra; Mitchell Schnall; Abass Alavi
Journal:  Breast Cancer Res Treat       Date:  2006-03-23       Impact factor: 4.872

8.  FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters.

Authors:  Andreas Buck; Holger Schirrmeister; Thorsten Kühn; Changxian Shen; Thomas Kalker; Jörg Kotzerke; Anja Dankerl; Gerhard Glatting; Sven Reske; Torsten Mattfeldt
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-07-26       Impact factor: 9.236

9.  Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation.

Authors:  F Crippa; E Seregni; R Agresti; C Chiesa; C Pascali; A Bogni; D Decise; V De Sanctis; M Greco; M G Daidone; E Bombardieri
Journal:  Eur J Nucl Med       Date:  1998-10

10.  Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer.

Authors:  A Gil-Rendo; F Martínez-Regueira; G Zornoza; M J García-Velloso; C Beorlegui; N Rodriguez-Spiteri
Journal:  Br J Surg       Date:  2009-02       Impact factor: 6.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.